Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00321217
Status:
UNKNOWN
Last Update Posted:
2012-08-16
First Post:
2006-05-02
Brief Title:
Pharmacogenomics of Anti-TNF Anti-tumor Necrosis Factor Treatment in Patients With Rheumatoid Arthritis
Sponsor:
Radboud University Medical Center
Organization:
Radboud University Medical Center
Study Overview
Official Title:
Pharmacogenomics of Anti-TNF Treatment in Patients With Rheumatoid Arthritis
Status:
UNKNOWN
Status Verified Date:
2011-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main aim of this study is to identify genetic markers at DNA and RNA level which are involved in the response to treatment with monoclonal antibodies against TNF in patients with rheumatoid arthritis
Detailed Description:
Rheumatoid Arthritis RA is a severe inflammatory disease and genetic factors are known to play an important role in its pathogenesis Genetic factors are also involved in determining the prognosis of RA Identifying the genetic factors that predispose to mild or aggressive RA is not easy and up to now only a few of these factors -like certain HLA-DR species- are known
The Rheumatology department of the Radboud University Nijmegen Medical Centre RUNMC has collected a unique inception cohort of over 500 patients with RA that have been followed from an early stage of disease for up to 10 years with detailed measurements of disease activity joint damage and other characteristics of disease progression
In this project we use this patient group to study polymorphisms in a large battery of genes for their effect on RA disease activityprogression
The Rheumatology department of the Radboud University Nijmegen Medical Centre RUNMC has collected a unique inception cohort of over 500 patients with RA that have been followed from an early stage of disease for up to 10 years with detailed measurements of disease activity joint damage and other characteristics of disease progression
In this project we use this patient group to study polymorphisms in a large battery of genes for their effect on RA disease activityprogression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None